Heparin Problems Renew Questions Of Liability

Law360, New York (February 15, 2008, 12:00 AM EST) -- As pharmaceutical company Baxter International Inc. investigates the four deaths and scores of allergic reactions linked to its blood thinner heparin, news that the drug's active ingredient was likely made in a Chinese factory has raised now-familiar concerns about the safety of Chinese exports, and complex questions of who's on the hook when pharmaceuticals are found to be toxic.

Many of China's exports have been under intense scrutiny in the last year, after a series of tainted Chinese-made goods were pulled from shelves, including toothpaste and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.